The article you requested is
Use of Atypical Antipsychotics in Refractory Depression and Anxiety
J Clin Psychiatry 2005;66(suppl 8):13-21
© Copyright 2017 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Treatment options for bipolar depression and treatment-resistant unipolar depression include augmentation
of antidepressant therapy with a nonantidepressant drug, including atypical antipsychotics.
Risperidone is effective in combination with fluvoxamine, paroxetine, or citalopram in treatment-resistant
unipolar depression, with reported remission rates of 61% to 76%. Olanzapine in combination
with fluoxetine is safe and effective in patients with bipolar depression and those with
fluoxetine-resistant unipolar depression. Ziprasidone and aripiprazole augmentation of various selective
serotonin reuptake inhibitors has been reported to be effective in refractory unipolar depression in
open-label studies. Data on use of quetiapine or clozapine as augmentation therapy for depression or
anxiety are not yet available. Further double-blind, placebo-controlled studies of augmentation of
antidepressants with atypical antipsychotics in refractory depression and anxiety are justified based
on the available literature.